Table 3. Efficacy summary stratified by... | American Society of Hematology

Table 3.

Efficacy summary stratified by allele burden

	Pacritinib	BAT including ruxolitinib*	P†
Patients with SVR_35%, n (%)	n = 369	n = 179
JAK2V617F allele burden‡
Negative	14/61 (23.0)	0/19 (0.0)	.033
>0%-25%	18/86 (20.9)	0/46 (0.0)	<.001
25%-50%	14/91 (15.4)	0/33 (0.0)	.020
50%-75%	9/53 (17.0)	1/26 (3.8)	.153
>75%	14/72 (19.4)	5/49 (10.2)	.209

Patients with reduction in MPN-SAF TSS ≥50%, n (%)	n = 249	n = 120
JAK2V617F allele burden‡
Negative	7/37 (18.9)	2/15 (13.3)	1.000
>0%-25%	17/66 (25.8)	3/39 (7.7)	.038
25%-50%	17/57 (29.8)	2/24 (8.3)	.046
50%-75%	6/38 (15.8)	2/14 (14.3)	1.000
>75%	9/47 (19.1)	5/24 (20.8)	1.000

	Pacritinib	BAT including ruxolitinib*	P†
Patients with SVR_35%, n (%)	n = 369	n = 179
JAK2V617F allele burden‡
Negative	14/61 (23.0)	0/19 (0.0)	.033
>0%-25%	18/86 (20.9)	0/46 (0.0)	<.001
25%-50%	14/91 (15.4)	0/33 (0.0)	.020
50%-75%	9/53 (17.0)	1/26 (3.8)	.153
>75%	14/72 (19.4)	5/49 (10.2)	.209

Patients with reduction in MPN-SAF TSS ≥50%, n (%)	n = 249	n = 120
JAK2V617F allele burden‡
Negative	7/37 (18.9)	2/15 (13.3)	1.000
>0%-25%	17/66 (25.8)	3/39 (7.7)	.038
25%-50%	17/57 (29.8)	2/24 (8.3)	.046
50%-75%	6/38 (15.8)	2/14 (14.3)	1.000
>75%	9/47 (19.1)	5/24 (20.8)	1.000

BAT group only included ruxolitinib in 20 evaluable patients from the PERSIST-2 cohort.

P values calculated by Fisher's exact test.

Patients with missing genomic data are not displayed.